BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 11326643)

  • 1. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
    Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
    Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
    Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma.
    Brockmann JG; Hernandez CA; Emparan C; Wolters H; Haier J; Dietl KH; Senninger NJ
    Anticancer Res; 2003; 23(2A):819-25. PubMed ID: 12820306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J; Schulze G
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer: longitudinal analyses.
    Mataki Y; Takao S; Maemura K; Mori S; Shinchi H; Natsugoe S; Aikou T
    Clin Cancer Res; 2004 Jun; 10(11):3807-14. PubMed ID: 15173089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers in hepatoma, gallbladder-biliary tract and pancreas cancer].
    Nakahara M; Fujisawa K
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3010-9. PubMed ID: 2445292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
    Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
    Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
    Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor markers in the diagnosis of tumors in the subhepatic area].
    Dufek V; Petrtýl J; Klener P; Chmel J
    Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
    Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory diagnosis of tumors of the pancreato-biliary area in patients with mechanical jaundice].
    Skvortsov SV; Lytsar' BN; Kalinin AV; Dolinskiĭ AG
    Klin Med (Mosk); 1992; 70(5-6):21-3. PubMed ID: 1279265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease.
    Halm U; Rohde N; Klapdor R; Reith HB; Thiede A; Etzrodt G; Mössner J; Keller T
    Anticancer Res; 2000; 20(6D):4957-60. PubMed ID: 11326646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor markers in the upper intestinal tract--stomach and pancreas].
    Pointner R; Conrad F; Schwab G
    Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.